Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.
This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight key trends and share some of the biggest changes at the top and bottom of the rankings year over year.
To learn more about the topics in this episode:

Avoiding 11th hour surprises in clinical trials (Sponsored)
18:42

What Xaira is building after its $1B fundraise
33:12

Patent expirations push biopharma industry toward a tougher 2026
17:32